Phase 2 Study of BGB-16673 in B-Cell Malignancies: Safety and Dose Findings

This Phase 1/2 study investigates the safety and optimal dosing of BGB-16673 in patients with various B-cell malignancies, including marginal zone lymphoma, follicular lymphoma, non-Hodgkin lymphoma, and Waldenström macroglobulinemia. The trial is structured in two parts: a Phase 1 dose-escalation and safety expansion phase, and a Phase 2 expansion cohort phase. The primary endpoints for Phase 1 include the number of participants experiencing adverse events, determination of the maximum tolerated dose (MTD) or maximum administered dose (MAD), and recommended dose(s) for expansion (RDFE). The study aims to enroll approximately 614 participants, with a primary completion date projected for November 2026. Safety and tolerability are key considerations, with adverse events being closely monitored to establish the MTD and RDFE. Although specific statistical outcomes such as hazard ratios or confidence intervals are not yet reported, the study's design focuses on ensuring the safety and efficacy of BGB-16673. Clinicians should be aware of the potential for adverse events and the importance of dose optimization in this patient population.

This study involves patients with B-cell malignancies, which are types of blood cancers like Marginal Zone Lymphoma and Follicular Lymphoma. Researchers are testing a new drug called BGB-16673 to find out the best dose to use and to see how safe it is for patients. In the first part of the study, they will gradually increase the dose to find the highest amount that patients can safely take without serious side effects. In the second part, they will give this dose to more patients to see how well it works. This could be important for patients because it might offer a new treatment option for these types of blood cancers. However, it’s still early in the research, and more studies are needed to understand the full effects of the drug and how it compares to existing treatments.